For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
